1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Annji Pharmaceutical Co., Ltd.

Annji Pharmaceutical Co., Ltd.

TTPEX:7754
69.00
TWD
-0.40
(-0.58%)
5.90BMarket Cap
Annji Pharmaceutical Co., Ltd.
TPEX:7754
(Taipei Exchange)

Recent

price

69.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
TTM
TWD
0.02
0.02
1.52
1.02
0.08
- -
Revenue per Share
-2.11
-3.58
-3.49
-3.75
-3.78
- -
Basic EPS, GAAP
-1.53
-2.9
-0.84
-2.08
-3.74
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
6.89
5.41
9.81
7.01
3.37
4.15
Book Value per Share
4.74
3.62
8.38
5.95
2.67
3.65
Tangible Book Value per Share
94
66
94
94
95
96
Basic Weighted Avg Shares
1
2
144
96
8
- -
Sales/Revenue/Turnover
-14,095.82
-14,790.59
-187.15
-373.4
-4,891.01
- -
Operating Margin (%)
42
40
38
45
45
- -
Depreciation Expense
-199
-237
-329
-354
-358
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-13,841.46
-14,554.12
-229.37
-367.02
-4,738.73
- -
Profit Margin (%)
396
275
691
453
267
354
Working Capital
- -
- -
55
49
43
39
LT Debt
650
511
925
662
320
419
Total Equity
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-40.78
-45.87
-44.61
-72.89
- -
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
6
6
7
LT Borrowings
- -
- -
- -
LT Finance Leases
46
43
39
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
95
95
101
Market Capitalization
2,104
4,816
5,905

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
543
370
491
Cash, Cash Equivalents & STI
506
348
460
Accounts Receivable, Net
- -
- -
- -
Inventories
27
18
21
Total Current Liabilities
109
103
137
Payables & Accruals
- -
- -
- -
ST Debt
6
6
7
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-51.7%
Free Cash Flow
- -
- -
80.14%
Net Income, GAAP
- -
- -
1.1%
Sales/Revenue/Turnover
- -
- -
-92.17%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
96
2025
- -
- -
8
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-3.75
2025
- -
- -
-3.78
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
AnnJi Pharmaceutical Co., Ltd. (7754.TWO) operates as a clinical-stage biopharmaceutical company focused on developing first-in-class small molecule new chemical entities (NCEs) targeting neurology, dermatology, and inflammatory disorders; its pipeline includes AJ201, a nuclear factor E2-related factor 2 (Nrf2) activator oral suspension for treating neurodegenerative diseases such as spinal and bulbar muscular atrophy (SBMA); AJ302, a highly selective histone deacetylase 6 (HDAC6) inhibitor sustained-release injection for preventing and treating chemotherapy-induced peripheral neuropathy (CIPN); AJ202, a next-generation scalp topical androgen degradation promoter for male pattern baldness (androgenetic alopecia); AJ303, an anti-fibrotic and anti-inflammatory compound for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases; and AJ101, a topical cream androgen receptor degradation enhancer with anti-inflammatory and antioxidant properties for acne vulgaris. Founded in 2014 and headquartered at 16F.-6, No. 508, Sec. 7, Zhongxiao E. Rd., Nangang Dist., Taipei City, Taiwan, the company directs its innovative drug projects primarily toward high-unmet-need indications, including orphan drugs, with products targeted at European and American markets. In recent developments, AnnJi listed its shares on the Taipei Exchange (TPEX) in June 2024; licensed intellectual property rights for AJ201 to partner Avenue Therapeutics in February 2023, though Avenue received a notice of intent to terminate from AnnJi in March 2025; and advanced its pipeline with Phase 1 clinical trials for AJ302 expected around 2021 alongside ongoing preclinical and early clinical efforts for other candidates amid 2025Q2 financial reporting.